Intacept (etanercept biosimilar) / Intas - LARVOL DELTA

Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience, for an Etanercept Biosimilar Targeting Autoimmune Diseases in more than 150 Countries, including Europe and the United States of America (PRNewswire) - "Intas Pharmaceuticals Ltd...announced today a strategic exclusive licensing agreement with mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) for a biosimilar for Etanercept. Etanercept is a dimeric fusion protein with tumor necrosis factor (TNF) blocking action that was approved for use over 20 years ago, offering patients a valuable therapeutic option for treating various autoimmune diseases. According to IQVIA, global sales of Etanercept for 12 months, ending June 2023, were $ 11B. This agreement accelerates Intas' global mission to enable innovative and affordable treatment options for autoimmune diseases."

Licensing / partnership • Ankylosing Spondylitis • Immunology • Psoriasis • Rheumatoid Arthritis

IL-17 Inhibitors for the Treatment of Plaque Psoriasis - Episode 7: Gaps in Plaque Psoriasis Care (DermatologyTimes) - "Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss gaps in care for the treatment of plaque psoriasis. Mark G. Lebwohl, MD: As the treatment landscape continues to evolve, what are some of the gaps that remain regarding the care of patients with moderate to severe psoriasis? How do you think these will be and should be addressed in the future? Alice B. Gottlieb, MD, PhD: There are subgroups of patients for which we have inadequate data. One of them is older adults. We don't have a lot of data because they're excluded from clinical trials for a variety of reasons. We don't have a lot of people of color. We don't have a lot of data on HIV-positive patients. In my clinic, I see HIV patients quite a bit."

Interview • Video • Psoriasis

Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. (PubMed, J Ocul Pharmacol Ther) - "Other drugs include anti-CD20 inhibitors (rituximab), interleukin-6R-inhibitor (tocilizumab), Interleukin-1R-inhibitor (anakinra), Iinterleukin-2-inhibitor (daclizumab), and the list is further increasing. New advances in biologics are the biosimilar molecules, which are biological products that are highly similar to the reference product, and they include Infimab (biosimilar of infliximab), Exemptia or Adfrar (biosimilar of adalimumab), and Intacept or Etacept (biosimilar of etanercept)...Thus, biologics are the future of uveitis treatment with promising results. This article aims to summarize the current knowledge on biologics and their clinical utility in the management of NIU."

Journal • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Ocular Inflammation • Oncology • Ophthalmology • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Uveitis • IL1R1 • IL2 • IL6R